---
title: "Treatment of systemic sclerosis and scleroderma disorders"
slug: "treatment-of-systemic-sclerosis-and-scleroderma-disorders"
date: "2023-08-05"
enableToc: false
tags:
  - building
---

> [!info]
>
> üå± ‰æÜËá™: [[systemic sclerosis and scleroderma disorders]]

# Treatment of systemic sclerosis and scleroderma disorders

- Minimize steroid exposure to reduce risk of renal crisis
- Interstitial lung disease:
  - tocilizumab (Lancet Respir Med 2020;8:963), MMF (‚Üì toxicity vs. cyclophosphamide; Lancet Respir Med 2020;8:304);
  - nintedanib (multikinase inhibitor/antifibrotic) a/w ‚Üì FVC decline (NEJM 2019; 380:2518).
  - PAH: pulmonary vasodilators (see ‚ÄúPulm Hypertension‚Äù); early Rx a/w better outcomes
- Renal crisis:
  - ACEI (not ARB) for Rx, not prophylaxis (Semin Arthritis Rheum 2015;44:687)
- GI:
  - PPI/H2-blockers for GERD;
  - promotility agents & antibx for bacterial overgrowth
- Cardiac:
  - NSAIDs ¬± colchicine superior to steroids for pericarditis
- Arthritis:
  - acetaminophen,
  - NSAIDs,
  - hydroxychloroquine,
  - MTX
- Myositis: MTX, AZA, steroids
- Skin:
  - PUVA for morphea. Pruritus: emollients, topical/oral steroids.
  - Fibrosis: MTX; MMF? (Ann Rheum Dis 2017;76:1207; Int J Rheum Dis 2017;20:481).
  - CYC if severe (NEJM 2006;354:2655).
- Auto-HSCT promising for severe disease (NEJM 2018;378:35)
